Loading…
TransMedics Group, Inc. is projected to rise to $84.60 by 2027, a +17% move from its current price of $72.19. TMDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $69.98 | $72.16 | $74.40 | -0.05% |
| Jul 13 | $69.07 | $72.12 | $75.31 | -0.09% |
| Jul 14 | $68.37 | $72.09 | $76.01 | -0.14% |
| Jul 15 | $67.78 | $72.06 | $76.60 | -0.18% |
| Jul 16 | $67.26 | $72.02 | $77.12 | -0.23% |
| Jul 17 | $66.79 | $71.99 | $77.59 | -0.28% |
| Jul 18 | $66.36 | $71.96 | $78.02 | -0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $66.36 | $71.96 | $78.02 | -0.32% |
| Week 2 | $63.97 | $71.72 | $80.42 | -0.64% |
| Week 3 | $62.14 | $71.49 | $82.25 | -0.97% |
| Week 4 | $60.61 | $71.26 | $83.78 | -1.29% |
| Week 5 | $59.27 | $71.03 | $85.12 | -1.60% |
| Week 6 | $58.07 | $70.80 | $86.33 | -1.92% |
| Week 7 | $56.97 | $70.57 | $87.42 | -2.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TransMedics Group, Inc. is a healthcare company in the medical technology sector focused on transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside of the human body.
Its OCS LUNG for preserving standard criteria donor lungs, OCS Heart for preservation and beating-heart support of donor hearts, and OCS Liver for donor livers form core components, and the company also developed a national OCS program and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. trades under the symbol TMDX in the Healthcare sector. The current price is $68.44 and the market capitalization is $2.37B, with a rank of 1912. The forecast outlines a path toward higher prices over time.
For 2026, the min is $62.04, the avg is $68.44, and the max is $87.41, with ROI 0 and sentiment NEUTRAL. From 2027 onward, the outlook becomes increasingly bullish, with the 2027 avg $85.84 and 2030 avg $108.50, and the long-range horizon showing a 2050 avg of $363.80 and a max of $687.52, along with rising ROI and bullish sentiment.
A major floor 17.2% below — a decisive break under it would weaken the trend.
The nearest floor, 8.0% below — buyers have tended to step in here.
The nearest ceiling, 9.1% above — a clean break opens room to run.
A major ceiling 105.0% above — clearing it would confirm fresh momentum.
Key TMDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TMDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.24 | Buy | $71.03 | Buy |
| MA 10 | $69.51 | Buy | $71.05 | Buy |
| MA 20 | $72.48 | Sell | $71.70 | Buy |
| MA 50 | $73.10 | Sell | $78.01 | Sell |
| MA 100 | $96.25 | Sell | $90.27 | Sell |
| MA 200 | $112.10 | Sell | $101.52 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.26 | Neutral |
| Stoch RSI (14) | 58.39 | Neutral |
| CCI (20) | -28.01 | Neutral |
| Williams %R (14) | -57.55 | Info |
| MACD (12,26,9) | 0.28 | Buy |
| ROC (12) | -3.52 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 42.45 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 63.29 | Neutral |
| Momentum (10) | -6.52 | Sell |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 72.21 | Sell |
| ADX (14) | 14.02 | Neutral |
| ATR (14) | 1.91 | Info |
The 30-day technical picture shows NEUTRAL sentiment with RSI14 at 50. The SMA50 is $81.42 and the SMA200 is $114.47, placing the price below near-term and long-term moving averages. The official support level sits at $62.04 while resistance is at $78.79.
The 30-day price range spans from $56.56 to $82.82, and the current price of $68.44 sits below the SMA50 but above the support level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.04 | $72.19 | $90.93 | 0% | Neutral | |
| $66.60 | $84.60 | $114.16 | +17% | Neutral | |
| $72.10 | $94.54 | $132.87 | +31% | Bullish | |
| $73.05 | $98.34 | $142.66 | +36% | Bullish | |
| $75.65 | $104.25 | $155.30 | +44% | Bullish | |
| $72.14 | $101.54 | $154.83 | +41% | Bullish | |
| $69.67 | $100.03 | $155.73 | +39% | Bullish | |
| $71.17 | $104.12 | $165.16 | +44% | Bullish | |
| $82.08 | $122.24 | $197.27 | +69% | Bullish | |
| $93.82 | $142.14 | $233.09 | +97% | Bullish | |
| $96.71 | $158.40 | $277.70 | +119% | Bullish | |
| $167.52 | $314.54 | $607.45 | +336% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $62.04 | $72.19 | $87.40 | +0.00% |
| August 2026 | $60.26 | $71.38 | $86.98 | -1.13% |
| September 2026 | $57.98 | $69.21 | $85.39 | -3.03% |
| October 2026 | $59.23 | $71.18 | $88.73 | +2.84% |
| November 2026 | $60.61 | $73.25 | $92.11 | +2.91% |
| December 2026 | $59.04 | $71.74 | $90.93 | -2.07% |
Click any year to see its month-by-month TMDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TransMedics Group, Inc.'s 2026 outlook centres on $72.19, within a $62.04 to $90.93 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, TMDX could reach as high as $114.16, with a base case around $84.60 and support toward $66.60 — roughly +17% from $72.19. A consolidation phase looks the most probable path here.
Expect TMDX to range from $72.10 to $132.87 through 2028. The $94.54 average target implies a +31% move from current prices. That is up +12% on the projected 2027 average. Momentum favours further upside here.
The TMDX price prediction for 2029 points to an average of $98.34 (low $73.05, high $142.66) — a potential gain of +36% on today's $72.19. Buyers look set to stay in control over this stretch.
In 2030, TMDX is projected to trade between $75.65 and $155.30, averaging $104.25 — a potential gain of +44% from today's $72.19. That is up +6% on the projected 2029 average. Momentum favours further upside here.
TransMedics Group, Inc.'s 2031 outlook centres on $101.54, within a $72.14 to $154.83 range. That is -3% versus the projected 2030 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, TMDX could reach as high as $155.73, with a base case around $100.03 and support toward $69.67 — roughly +39% from $72.19. Momentum favours further upside here.
Expect TMDX to range from $71.17 to $165.16 through 2033. The $104.12 average target implies a +44% move from current prices. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The TMDX price prediction for 2034 points to an average of $122.24 (low $82.08, high $197.27) — a potential gain of +69% on today's $72.19. Momentum favours further upside here.
In 2035, TMDX is projected to trade between $93.82 and $233.09, averaging $142.14 — a potential gain of +97% from today's $72.19. That is up +16% on the projected 2034 average. Buyers look set to stay in control over this stretch.
TransMedics Group, Inc.'s 2040 outlook centres on $158.40, within a $96.71 to $277.70 range. That is up +11% on the projected 2035 average. That marks a +119% change versus current levels. Momentum favours further upside here.
By 2050, TMDX could reach as high as $607.45, with a base case around $314.54 and support toward $167.52 — roughly +336% from $72.19. Buyers look set to stay in control over this stretch.
Investing $1,000 in TMDX today (≈ 13.852334 TMDX) could be worth
$4,357.13
+$3,357.13 (+336%) by 2050 · US Dollar
Based on the average projected TMDX price of $314.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TMDXwould be worth at today's price.
$1,000 invested in TMDX on Jul 10, 2025 (≈ 8.014105 TMDX) would be worth
$578.54
-$421.46 (-42.1%) today · 0.58× · US Dollar
Based on a TMDX entry price of $124.78 vs. today's $72.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $68.86 | $1,048.36 | +4.8% |
| 1 month ago | $74.77 | $965.49 | -3.5% |
| 3 months ago | $114 | $633.25 | -36.7% |
| 6 months ago | $134.66 | $536.09 | -46.4% |
| 1 year ago | $124.78 | $578.54 | -42.1% |
| All time (5.0y) ago | $33.45 | $2,158.15 | +115.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TMDX forecast.
Our base-case forecast reaches $140.00 around 2035.
Implied market cap at $140.00: $4.84B
The multi-year forecast portrays a bullish trajectory across the horizon. In 2027 the avg is $85.84 with a min of $67.87 and a max of $115.14, and ROI of 25.4; in 2028 the avg is $94.88 with a max of $132.25 and ROI 38.6; in 2029 the avg is $98.62 with a max of $141.66 and ROI 44.1. By 2030 the avg reaches $108.50 with a max of $159.84 and ROI 58.5.
The 2031–2032 estimates show continued bullish momentum, with 2033 avg $116.94 and max $182.91, and 2034 avg $135.95 with max $216.17. Long-range forecasts extend to 2040 with avg $180.96 and max $311.54 (ROI 164.4), and to 2050 with avg $363.80 and max $687.52 (ROI 431.6), maintaining a bullish sentiment across the horizon. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
2030 avg price $108.50; min $79.53; max $159.84; ROI 58.5; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages (2027 avg $85.84, 2028 avg $94.88, 2029 avg $98.62, 2030 avg $108.50) and ROI up to 431.6 by 2050; these are estimates.
The forecasted max price for 2030 is $159.84; later years show higher max values (2033 $182.91, 2034 $216.17, 2050 $687.52).
Current price $68.44; Market cap $2.37B.
Sentiment NEUTRAL; RSI14 50; SMA50 $81.42; SMA200 $114.47; Support $62.04; Resistance $78.79; 30-day range low $56.56 high $82.82.
TransMedics Group, Inc. Community Discussion
0Share your TransMedics Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.